DMCs offer an opportunity for a team of experts, independent from the trial sponsor, to examine the interim clinical data and make unbiased recommendations for the continuation, alteration and termination of the trial. Incorporating DMCs into trial design and conduct adds additional protection against proceeding with an unsafe product or futile trial design which mitigates risk to subjects, optimizes resource utilization for the sponsor by reassuring study integrity and protects the public from access to unsafe products.

"ExL’s DMC Conference expanded my knowledge of the processes and procedures associated with DMC services and gave me insight into regulatory compliance issues."
- Rhonda Rusinski, RN, BSN, Drug Safety Manager, ICON Clinical Research

Questions? Comments?
Please contact Program Director Kristen Hunter, 212-400-6241, khunter@exlpharma.com